Organon & Co.
corporate_fare Company Profile
Organon & Co. (NYSE:OGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for OGN at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Sun Pharma Boosts Organon Takeover Offer to $13 Billion, Driving Shares Up 22%
- Sun Pharma Reportedly Offers $12 Billion for Organon, Stock Jumps 41%
- Audit Committee Concludes Review, Finds No Improper Conduct or Financial Adjustments Needed
- Organon Reports Q4 Net Loss Driven by $301M Goodwill Impairment; Audit Review Initiated
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$6.22B
Net Income
$187M
Diluted EPS
$0.72
Op. Cash Flow
$700M
Free Cash Flow
$538M
Gross Profit
$3.31B
Cash & Equivalents
$574M
Total Debt
$8.64B
Debt / Equity
11.49×
Net Margin
3.0%
Shares Outstanding
260.32M sh
Source: 10-K · filed 2026-02-24 · accession 0001628280-26-011125
show_chartPrice Chart
Loading chart...
feed OGN - Filings & News (Page 2)
OGN
Apr 24, 2026, 1:09 PM EDT
Price at Filing:
$11.05
Real-time Price:
$13.89
Change:
+$2.85 (+26%)
Market Cap:
$3.648B
OGN
Apr 10, 2026, 10:01 AM EDT
Price at Filing:
$8.46
Real-time Price:
$13.89
Change:
+$5.44 (+64%)
Market Cap:
$3.648B
OGN
Feb 20, 2026, 7:30 AM EST
Price at Filing:
$8.03
Real-time Price:
$13.89
Change:
+$5.86 (+73%)
Market Cap:
$3.648B
OGN
Feb 12, 2026, 7:45 AM EST
Price at Filing:
$7.39
Real-time Price:
$13.89
Change:
+$6.50 (+88%)
Market Cap:
$3.648B